Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Thromb Res. 2013 Nov 16;133(2):222–228. doi: 10.1016/j.thromres.2013.11.009

Fig. 4.

Fig. 4

Effect of ERK1/2 inhibitor on anti-hPS Ab-induced TF expression and activity in HCAECs. (A). Effect of ERK1/2 inhibitor on anti-hPS Ab-induced TF mRNA expression in HCAECs. Serum-starved HCAECs we incubated with anti-hPS Ab or anti-hTF Ab, with the presence or absence of ERK1/2 inhibitor (U0126) for 3 hours. TF mRNA expression was measured by real-time PCR (BioRad). The relative amount of TF mRNA was normalized to β-actin. Data shown are the mean + SEM of triplicate determinations. (B). Effect of MEK1/2 inhibitor on anti-hPS Ab-induced TF protein activity in HCAECs. Serum-starved HCAECs were incubated with anti-hPS Ab or anti-hTF Ab, with the presence or absence of ERK1/2 inhibitor (U0126) for 3 hours. The cellular TF activity was measured by IMUBIND Tissue Factor ELISA Kit. Data shown are the mean + SEM of duplicate determinations. **P < 0.01 versus untreated controls. #P < 0.01 versus anti-hPS Ab group.